Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) was downgraded by stock analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued on Tuesday, Zacks reports.
ZLDPF has been the subject of several other research reports. Jefferies Financial Group cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Barclays lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 8th. Finally, Wells Fargo & Company reaffirmed an “overweight” rating on shares of Zealand Pharma A/S in a report on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Zealand Pharma A/S presently has a consensus rating of “Hold”.
Check Out Our Latest Report on ZLDPF
Zealand Pharma A/S Price Performance
Shares of OTCMKTS:ZLDPF opened at $36.75 on Tuesday. The firm has a market capitalization of $2.63 billion, a PE ratio of 6.09 and a beta of 0.99. Zealand Pharma A/S has a 1 year low of $33.08 and a 1 year high of $83.12. The company has a debt-to-equity ratio of 0.02, a current ratio of 13.98 and a quick ratio of 13.98. The firm’s 50-day moving average is $38.85 and its two-hundred day moving average is $46.81.
About Zealand Pharma A/S
Zealand Pharma A/S is a biotechnology company headquartered in Copenhagen, Denmark. Founded in 1998, it discovers and develops peptide-based medicines, with a focus on metabolic diseases and rare conditions. The company’s portfolio has included Zegalogue (dasiglucagon), an injectable treatment approved in the United States for severe hypoglycemia in people with diabetes. Zealand also develops investigational medicines for areas such as obesity, liver disease and rare gastrointestinal disorders, and works with pharmaceutical partners to advance and commercialize selected programs.
Featured Articles
- Five stocks we like better than Zealand Pharma A/S
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
